Shire (LON:SHP)‘s stock had its “buy” rating reiterated by analysts at Citigroup in a research note issued on Friday.

SHP has been the subject of several other research reports. Goldman Sachs Group reaffirmed a “conviction-buy” rating on shares of Shire in a research note on Tuesday, October 17th. Shore Capital reaffirmed a “buy” rating on shares of Shire in a research note on Monday, November 13th. Liberum Capital reduced their price objective on shares of Shire from GBX 4,400 ($58.83) to GBX 4,200 ($56.16) and set a “hold” rating for the company in a research note on Tuesday, October 24th. Morgan Stanley reduced their price objective on shares of Shire from GBX 5,800 ($77.55) to GBX 5,700 ($76.21) and set an “overweight” rating for the company in a research note on Thursday, October 12th. Finally, HSBC dropped their target price on shares of Shire from GBX 4,050 ($54.15) to GBX 3,800 ($50.81) and set a “hold” rating for the company in a research report on Tuesday, November 21st. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of GBX 5,272.22 ($70.49).

Shire (SHP) opened at GBX 3,896.50 ($52.10) on Friday. The company has a market cap of $35,250.00 and a P/E ratio of 2,974.43. Shire has a 12 month low of GBX 3,435.50 ($45.94) and a 12 month high of GBX 5,067 ($67.75).

In other Shire news, insider Dominic Blakemore acquired 165 shares of the stock in a transaction dated Tuesday, December 19th. The stock was purchased at an average cost of GBX 3,790 ($50.68) per share, for a total transaction of £6,253.50 ($8,361.41).

COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/05/shire-shp-receives-buy-rating-from-citigroup.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.